270 related articles for article (PubMed ID: 15294183)
1. Ribozyme-mediated induction of apoptosis in human cancer cells by targeted repair of mutant p53 RNA.
Shin KS; Sullenger BA; Lee SW
Mol Ther; 2004 Aug; 10(2):365-72. PubMed ID: 15294183
[TBL] [Abstract][Full Text] [Related]
2. Trans-splicing repair of mutant p53 suppresses the growth of hepatocellular carcinoma cells in vitro and in vivo.
He X; Liu F; Yan J; Zhang Y; Yan J; Shang H; Dou Q; Zhao Q; Song Y
Sci Rep; 2015 Mar; 5():8705. PubMed ID: 25732051
[TBL] [Abstract][Full Text] [Related]
3. Gene expression responses in vivo by human telomerase reverse transcriptase (hTERT)-targeting trans-splicing ribozyme.
Song MS; Jeong JS; Cho KS; Lee SW
Exp Mol Med; 2007 Dec; 39(6):722-32. PubMed ID: 18160843
[TBL] [Abstract][Full Text] [Related]
4. Functional repair of p53 mutation in colorectal cancer cells using trans-splicing.
He X; Liao J; Liu F; Yan J; Yan J; Shang H; Dou Q; Chang Y; Lin J; Song Y
Oncotarget; 2015 Feb; 6(4):2034-45. PubMed ID: 25576916
[TBL] [Abstract][Full Text] [Related]
5. A transcriptional activation function of p53 is dispensable for and inhibitory of its apoptotic function.
Kokontis JM; Wagner AJ; O'Leary M; Liao S; Hay N
Oncogene; 2001 Feb; 20(6):659-68. PubMed ID: 11313999
[TBL] [Abstract][Full Text] [Related]
6. Identification of p53-46F as a super p53 with an enhanced ability to induce p53-dependent apoptosis.
Nakamura Y; Futamura M; Kamino H; Yoshida K; Nakamura Y; Arakawa H
Cancer Sci; 2006 Jul; 97(7):633-41. PubMed ID: 16827804
[TBL] [Abstract][Full Text] [Related]
7. Functional repair of a mutant chloride channel using a trans-splicing ribozyme.
Rogers CS; Vanoye CG; Sullenger BA; George AL
J Clin Invest; 2002 Dec; 110(12):1783-9. PubMed ID: 12488428
[TBL] [Abstract][Full Text] [Related]
8. Ribozyme targeted on HPV16E6 mRNA induced apoptosis on human cervical carcinoma CaSKi cells.
Zheng YF; Zhang JR
Ai Zheng; 2003 May; 22(5):458-62. PubMed ID: 12753702
[TBL] [Abstract][Full Text] [Related]
9. Specific and Efficient Regression of Cancers Harboring KRAS Mutation by Targeted RNA Replacement.
Kim SJ; Kim JH; Yang B; Jeong JS; Lee SW
Mol Ther; 2017 Feb; 25(2):356-367. PubMed ID: 28153088
[TBL] [Abstract][Full Text] [Related]
10. Human lymphoblastoid cell lines expressing mutant p53 exhibit decreased sensitivity to cisplatin-induced cytotoxicity.
Piovesan B; Pennell N; Berinstein NL
Oncogene; 1998 Nov; 17(18):2339-50. PubMed ID: 9811465
[TBL] [Abstract][Full Text] [Related]
11. Selective regression of cancer cells expressing a splicing variant of AIMP2 through targeted RNA replacement by trans-splicing ribozyme.
Won YS; Lee SW
J Biotechnol; 2012 Mar; 158(1-2):44-9. PubMed ID: 22285955
[TBL] [Abstract][Full Text] [Related]
12. Expression of cell-cycle mediators in ovarian cancer cells after transfection with p16(INK4a), p21(WAF1/Cip-1), and p53.
Ramirez PT; Gershenson DM; Tortolero-Luna G; Ramondetta LM; Fightmaster D; Wharton JT; Wolf JK
Gynecol Oncol; 2001 Dec; 83(3):543-8. PubMed ID: 11733969
[TBL] [Abstract][Full Text] [Related]
13. Gamma interferon-inducible protein 10 induces HeLa cell apoptosis through a p53-dependent pathway initiated by suppression of human papillomavirus type 18 E6 and E7 expression.
Zhang HM; Yuan J; Cheung P; Chau D; Wong BW; McManus BM; Yang D
Mol Cell Biol; 2005 Jul; 25(14):6247-58. PubMed ID: 15988033
[TBL] [Abstract][Full Text] [Related]
14. [Construction of a trans-splicing ribozyme for restoring EGFP truncation mutation].
Li B; Xiong YQ; Tu HB; Liu QC; Zou DT; Zhou WQ; Chen YY
Sheng Wu Gong Cheng Xue Bao; 2005 Sep; 21(5):748-53. PubMed ID: 16285516
[TBL] [Abstract][Full Text] [Related]
15. A recombinant defective adenoviral agent expressing anti-bcl-2 ribozyme promotes apoptosis of bcl-2-expressing human prostate cancer cells.
Dorai T; Perlman H; Walsh K; Shabsigh A; Goluboff ET; Olsson CA; Buttyan R
Int J Cancer; 1999 Sep; 82(6):846-52. PubMed ID: 10446452
[TBL] [Abstract][Full Text] [Related]
16. Adenovirus-mediated p53 gene therapy in pediatric soft-tissue sarcoma cell lines: sensitization to cisplatin and doxorubicin.
Ganjavi H; Gee M; Narendran A; Freedman MH; Malkin D
Cancer Gene Ther; 2005 Apr; 12(4):397-406. PubMed ID: 15618970
[TBL] [Abstract][Full Text] [Related]
17. Development and validation of sensitive assays to quantitate gene expression after p53 gene therapy and paclitaxel chemotherapy using in vivo dosing in tumor xenograft models.
Wen SF; Xie L; McDonald M; DiGiacomo R; Chang A; Gurnani M; Shi B; Liu S; Indelicato SR; Hutchins B; Nielsen LL
Cancer Gene Ther; 2000 Nov; 7(11):1469-80. PubMed ID: 11129289
[TBL] [Abstract][Full Text] [Related]
18. Downregulation of bcl-2 expression in lymphoma cells by bcl-2 ARE-targeted modified, synthetic ribozyme.
Luzi E; Papucci L; Schiavone N; Donnini M; Lapucci A; Tempestini A; Witort E; Nicolin A; Capaccioli S
Cancer Gene Ther; 2003 Mar; 10(3):201-8. PubMed ID: 12637941
[TBL] [Abstract][Full Text] [Related]
19. Mutant p53 mediated induction of cell cycle arrest and apoptosis at G1 phase by 9-hydroxyellipticine.
Sugikawa E; Hosoi T; Yazaki N; Gamanuma M; Nakanishi N; Ohashi M
Anticancer Res; 1999; 19(4B):3099-108. PubMed ID: 10652599
[TBL] [Abstract][Full Text] [Related]
20. Characterization of the molecular mechanisms for p53-mediated differentiation.
Chylicki K; Ehinger M; Svedberg H; Gullberg U
Cell Growth Differ; 2000 Nov; 11(11):561-71. PubMed ID: 11095245
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
